BeStock  

Bio-Rad Laboratories BIO

US equityMarket cap rank #1437Medical Devices
$358.90 −$8.60 (-2.34%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $358.90 0.00%
Open$364.34
Prev close$367.50
Day range$353.31 – $369.44
Volume182.3K
Market cap$9.65B
P/E (TTM)9.5
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership88.7%+0.12 pts vs. prior quarter
Institutions holding490+12 vs. prior quarter
Insider trades (recent)29 buys / 21 sellsNet buying
Short interest4.33% of floatDays to cover 5.1 · as of 30 Oct 2026
Short-sale volume share29.7%5-day average of daily volume

Short-sale volume as % of daily volume

13%22%31%40%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$6.99M (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

−$6.6MSuper−$438.6KBig−$1.8MMid+$503.1KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 38.8% of shares outstanding.

Largest holders

  • Blue Raven Partners, L.P.15.10%
  • First Eagle Investment Management, LLC9.13%
  • BlackRock6.47%
  • Norman Schwartz4.56%
  • Capital Research3.55%
  • Dimensional Fund Advisors3.29%
  • Vanguard Capital Management, LLC3.08%
  • Ariel Investments, LLC3.04%

By investor type

  • Mutual Fund60.27%
  • Private Company16.16%
  • Public Company5.40%
  • Hedge Fund5.30%
  • Individual/Insider4.75%
  • Government Pension Fund0.86%
  • Sovereign Wealth Fund0.42%
  • Insurance Company0.16%

Reported short interest has fallen from 4.97% to 4.33% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q3 +215,747 0.8%
Morgan Stanley Public Company 2026/Q3 +116,836 1.1%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +116,836 1.1%
Acadian Asset Management LLC Mutual Fund 2026/Q3 +104,770 0.5%
Victory Capital Management Inc. Mutual Fund 2026/Q3 +65,962 0.7%
Capital Research Mutual Fund 2026/Q3 +49,604 3.6%
BlackRock Mutual Fund 2026/Q3 +41,407 6.5%
Barclays PLC Public Company 2026/Q3 +32,557 1.1%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +24,013 0.1%
The Goldman Sachs Group, Inc. Public Company 2026/Q3 +112,244 0.5%
Nomura Holdings, Inc. Public Company 2026/Q3 +111,555 1.2%
Neuberger Berman Investment Advisers LLC Mutual Fund 2026/Q3 +108,783 0.4%
SG Americas Securities, LLC Private Company 2026/Q3 +103,817 0.6%
Victory Capital Management Inc. Mutual Fund 2026/Q3 +103,487 0.5%
AQR Capital Management Hedge Fund 2026/Q3 +98,209 0.7%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
9 Nov 2026 Courtney Enloe General Counsel Open Market Disposition -902 $386.17 750
8 Nov 2026 Jonathan DiVincenzo President Open Market Disposition -919 $390.47 1,962
8 Nov 2026 James Barry Executive VP & President of Life Science Group Open Market Disposition -1,400 $385.63 625
23 Oct 2026 Jonathan DiVincenzo President Derivative Exercise and Sale -951 $369.95 2,881
23 Oct 2026 Jonathan DiVincenzo President Derivative Exercise and Retained +918 – 2,881
19 Oct 2026 Sedat Evran Executive Vice President of Global Supply Chain Derivative Exercise and Sale -487 $354.50 4,160
19 Oct 2026 Sedat Evran Executive Vice President of Global Supply Chain Derivative Exercise and Retained +557 – 4,160
5 Sep 2026 Norman Schwartz Chairperson & CEO Derivative Exercise and Sale -4,730 $386.11 812,663
5 Sep 2026 Norman Schwartz Chairperson & CEO Derivative Exercise and Retained +2,834 – 812,663
5 Sep 2026 Roop Lakkaraju Chief Financial Officer Derivative Exercise and Sale -1,341 $386.11 4,151
5 Sep 2026 Roop Lakkaraju Chief Financial Officer Derivative Exercise and Retained +1,565 – 4,151
5 Sep 2026 Eva Engelhardt Executive VP & President of the Clinical Diagnostics Group Derivative Exercise and Sale -854 $386.11 1,828
5 Sep 2026 Eva Engelhardt Executive VP & President of the Clinical Diagnostics Group Derivative Exercise and Retained +1,325 – 1,828
5 Sep 2026 Allison Schwartz Director Derivative Exercise and Sale -116 $386.11 1,734
5 Sep 2026 Allison Schwartz Director Derivative Exercise and Retained +204 – 1,734
5 Sep 2026 James Barry Executive VP & President of Life Science Group Derivative Exercise and Sale -839 $386.11 2,025
5 Sep 2026 James Barry Executive VP & President of Life Science Group Derivative Exercise and Retained +1,244 – 2,025
5 Sep 2026 Sedat Evran Executive Vice President of Global Supply Chain Derivative Exercise and Sale -606 $386.11 3,603
5 Sep 2026 Sedat Evran Executive Vice President of Global Supply Chain Derivative Exercise and Retained +1,285 – 3,603
5 Sep 2026 Courtney Enloe General Counsel Derivative Exercise and Sale -551 $386.11 1,652

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 1,156,915 4.3% 5.1
15 Oct 2026 1,097,562 4.1% 4.8
30 Sep 2026 1,182,765 4.4% 4.3
15 Sep 2026 998,654 3.7% 3.8
31 Aug 2026 1,130,298 4.2% 4.2
14 Aug 2026 1,327,739 5.0% 4.8

Discussion

No comments yet — be the first to weigh in on BIO.

Sign in to join the discussion.

Scroll to Top